Xospata patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8969336 ASTELLAS Diamino heterocyclic carboxamide compound
Jan, 2031

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9487491 ASTELLAS Diamino heterocyclic carboxamide compound
Jul, 2030

(6 years from now)

US10786500 ASTELLAS Stable pharmaceutical composition for oral administration
Jul, 2036

(12 years from now)

Xospata is owned by Astellas.

Xospata contains Gilteritinib Fumarate.

Xospata has a total of 3 drug patents out of which 0 drug patents have expired.

Xospata was authorised for market use on 28 November, 2018.

Xospata is available in tablet;oral dosage forms.

Xospata can be used as treatment of acute myeloid leukemia (aml).

Drug patent challenges can be filed against Xospata from 2022-11-28.

The generics of Xospata are possible to be released after 01 July, 2036.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 28, 2025
New Chemical Entity Exclusivity (NCE) Nov 28, 2023

Drugs and Companies using GILTERITINIB FUMARATE ingredient

NCE-1 date: 2022-11-28

Market Authorisation Date: 28 November, 2018

Treatment: Treatment of acute myeloid leukemia (aml)


How can I launch a generic of XOSPATA before it's drug patent expiration?
More Information on Dosage

XOSPATA family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic